Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 6313242, 13 pages
https://doi.org/10.1155/2019/6313242
Review Article

A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

1Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan 16150, Malaysia
2Department of Immunology and Pathology, Monash University, Melbourne 3168, Australia
3School of Chemical Engineering, Universiti Sains Malaysia, Penang 14300, Malaysia
4State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, China
5School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia
6Hospital Universiti Sains Malaysia, Universiti Sains Malaysia, Kelantan 16150, Malaysia

Correspondence should be addressed to Rohimah Mohamud; ym.msu@mhamihor

Received 28 February 2019; Accepted 23 April 2019; Published 23 May 2019

Guest Editor: Subash C. Gupta

Copyright © 2019 Mohammad A. I. Al-Hatamleh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. W. Whatmore, “Nanotechnology—what is it? should we be worried?” Occupational Medicine, vol. 56, no. 5, pp. 295–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. “History of Nanotechnology,” TryNano.org, 2002, http://www.trynano.org/about/history-nanotechnology.
  3. D. Colman, “Richard Feynman introduces the world to nanotechnology with two seminal lectures (1959 & 1984),” Open Culture, 2013. View at Google Scholar
  4. C. Chan, “From Nanotech to Nanoscience,” Distillations, 2008. View at Google Scholar
  5. K. K. Jain, “Nanomedicine: application of nanobiotechnology in medical practice,” Medical Principles and Practice, vol. 17, no. 2, pp. 89–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. O. C. Farokhzad and R. Langer, “Impact of nanotechnology on drug delivery,” ACS Nano, vol. 3, no. 1, pp. 16–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Z. Mirza and F. A. Siddiqui, “Nanomedicine and drug delivery: a mini review,” International Nano Letters, vol. 4, no. 1, p. 94, 2014. View at Publisher · View at Google Scholar
  8. M. Alavi, N. Karimi, and M. Safaei, “Application of various types of liposomes in drug delivery systems,” Advanced Pharmaceutical Bulletin (APB), vol. 7, no. 1, pp. 3–9, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Rivera, “Liposomal anthracyclines in metastatic breast cancer: clinical update,” The Oncologist, vol. 8, Supplement 2, pp. 3–9, 2003. View at Google Scholar · View at Scopus
  10. A. Di Paolo, “Liposomal anticancer therapy: pharmacokinetic and clinical aspects,” Journal of Chemotherapy, vol. 16, Supplement 4, pp. 90–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Wu, Y. Zhang, D. Yang et al., “Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study,” International Journal of Nanomedicine, vol. 14, pp. 75–85, 2019. View at Publisher · View at Google Scholar
  12. E. Christensen, J. R. Henriksen, J. T. Jørgensen et al., “Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts,” International Journal of Nanomedicine, vol. 13, pp. 7647–7656, 2018. View at Publisher · View at Google Scholar
  13. M. J. Cloninger, “Biological applications of dendrimers,” Current Opinion in Chemical Biology, vol. 6, no. 6, pp. 742–748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Sharma, K. Liaw, R. Sharma, Z. Zhang, S. Kannan, and R. M. Kannan, “Targeting mitochondrial dysfunction and oxidative stress in activated microglia using dendrimer-based therapeutics,” Theranostics, vol. 8, no. 20, pp. 5529–5547, 2018. View at Publisher · View at Google Scholar
  15. S. Lu, X. Li, J. Zhang, C. Peng, M. Shen, and X. Shi, “Dendrimer‐stabilized gold nanoflowers embedded with ultrasmall iron oxide nanoparticles for multimode imaging–guided combination therapy of tumors,” Advanced Science, vol. 5, no. 12, p. 1801612, 2018. View at Publisher · View at Google Scholar
  16. R. Duncan, “The dawning era of polymer therapeutics,” Nature Reviews Drug Discovery, vol. 2, no. 5, pp. 347–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Wang, M. J. Seo, M. B. Deci, B. R. Weil, J. M. Canty, and J. Nguyen, “Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction,” International Journal of Nanomedicine, vol. 13, pp. 6441–6451, 2018. View at Publisher · View at Google Scholar
  18. S. Bai, X. Zhang, X. Ma et al., “Acid-active supramolecular anticancer nanoparticles based on cyclodextrin polyrotaxanes damaging both mitochondria and nuclei of tumor cells,” Biomaterials Science, vol. 6, no. 12, pp. 3126–3138, 2018. View at Publisher · View at Google Scholar
  19. M. O. Oyewumi and R. J. Mumper, “Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy,” Bioconjugate Chemistry, vol. 13, no. 6, pp. 1328–1335, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Mosafer, M. Teymouri, K. Abnous, M. Tafaghodi, and M. Ramezani, “Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells,” Materials Science and Engineering C: Materials for Biological Applications, vol. 72, pp. 123–133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. L. R. Hirsch, R. J. Stafford, J. A. Bankson et al., “Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 100, no. 23, pp. 13549–13554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Xu, Y. Bayazitoglu, and A. Meade Jr., “Evaluation of theranostic perspective of gold-silica nanoshell for cancer nano-medicine: a numerical parametric study,” Lasers in Medical Science, 2018. View at Google Scholar · View at Scopus
  23. S. E. Park, J. Lee, T. Lee et al., “Comparative hyperthermia effects of silica-gold nanoshells with different surface coverage of gold clusters on epithelial tumor cells,” International Journal of Nanomedicine, vol. 10, pp. 261–271, 2015. View at Publisher · View at Google Scholar
  24. N. W. S. Kam, M. O'Connell, J. A. Wisdom, and H. Dai, “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 102, no. 33, pp. 11600–11605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-M. Lin and T.-Y. Lu, “C60 fullerene derivatized nanoparticles and their application to therapeutics,” Recent Patents on Nanotechnology, vol. 6, no. 2, pp. 105–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Wang, C. Jin, H. Liang, Y. Tang, H. Zhang, and Y. Yang, “Effects of fullerene C(6)(0) nanoparticles on A549 cells,” Environmental Toxicology and Pharmacology, vol. 37, no. 2, pp. 656–661, 2014. View at Publisher · View at Google Scholar
  27. K.-T. Yong, J. Qian, I. Roy et al., “Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells,” Nano Letters, vol. 7, no. 3, pp. 761–765, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Shegokar and R. H. Müller, “Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives,” International Journal of Pharmaceutics, vol. 399, no. 1-2, pp. 129–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Fuhrmann, M. A. Gauthier, and J.-C. Leroux, “Targeting of injectable drug nanocrystals,” Molecular Pharmaceutics, vol. 11, no. 6, pp. 1762–1771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Yan and R. Kopelman, “The embedding of meta‐tetra (Hydroxyphenyl)‐chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH‐dependent optical properties,” Photochemistry and Photobiology, vol. 78, no. 6, pp. 587–591, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Meka, L. Jenkins, M. Dàvalos-Salas et al., “Enhanced solubility, permeability and anticancer activity of vorinostat using tailored mesoporous silica nanoparticles,” Pharmaceutics, vol. 10, no. 4, p. 283, 2018. View at Publisher · View at Google Scholar
  32. R. Rosenbrand, D. Barata, P. Sutthavas et al., “Lipid surface modifications increase mesoporous silica nanoparticle labeling properties in mesenchymal stem cells,” International Journal of Nanomedicine, vol. Volume 13, pp. 7711–7725, 2018. View at Publisher · View at Google Scholar
  33. Z. Li, S. Tan, S. Li, Q. Shen, and K. Wang, “Cancer drug delivery in the nano era: an overview and perspectives (Review),” Oncology Reports, vol. 38, no. 2, pp. 611–624, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Schulte, J. Bernhagen, and R. Bucala, “Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view,” Mediators of Inflammation, vol. 2013, Article ID 165974, 16 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Moses, V. Edwards, and E. Brantley, “Cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells, without harming MCF-10A healthy cells,” Journal of Nanomedicine & Nanotechnology, vol. 7, no. 369, p. 2, 2016. View at Publisher · View at Google Scholar
  36. M. Roser and R. Hannah, “Cancer,” Our World in Data, 2018. View at Google Scholar
  37. G. Landskron, M. de La Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, “Chronic inflammation and cytokines in the tumor microenvironment,” Journal of Immunology Research, vol. 2014, Article ID 149185, 19 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Bazzoni and B. Beutler, “The tumor necrosis factor ligand and receptor families,” The New England Journal of Medicine, vol. 334, no. 26, pp. 1717–1725, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Ahmad, A. A. Zamry, H.-T. T. Tan, K. K. Wong, J. Lim, and R. Mohamud, “Targeting dendritic cells through gold nanoparticles: a review on the cellular uptake and subsequent immunological properties,” Molecular Immunology, vol. 91, pp. 123–133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. D. J. MacEwan, “TNF ligands and receptors–a matter of life and death,” British Journal of Pharmacology, vol. 135, no. 4, pp. 855–875, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Onizawa, T. Nagaishi, T. Kanai et al., “Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 296, no. 4, pp. G850–G859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. T. N. Seyfried, R. E. Flores, A. M. Poff, and D. P. D'Agostino, “Cancer as a metabolic disease: implications for novel therapeutics,” Carcinogenesis, vol. 35, no. 3, pp. 515–527, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Ma and H. Yu, “Global burden of cancer,” Yale Journal of Biology and Medicine, vol. 79, no. 3-4, pp. 85–94, 2006. View at Google Scholar
  45. H. N. Banerjee and M. Verma, “Application of nanotechnology in cancer,” Technology in Cancer Research & Treatment, vol. 7, no. 2, pp. 149–154, 2008. View at Publisher · View at Google Scholar
  46. Y. Mi, Z. Shao, J. Vang, O. Kaidar-Person, and A. Z. Wang, “Application of nanotechnology to cancer radiotherapy,” Cancer Nanotechnol, vol. 7, no. 1, p. 11, 2016. View at Google Scholar
  47. M. E. Werner, M. B. Foote, and A. Z. Wang, “Chemoradiotherapy of human tumors: Novel approaches from nanomedicine,” Current Pharmaceutical Design, vol. 18, no. 19, pp. 2830–2837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. L. A. Torre, F. Islami, R. L. Siegel, E. M. Ward, and A. Jemal, “Global cancer in women: burden and trends,” Cancer Epidemiology, Biomarkers & Prevention, vol. 26, no. 4, pp. 444–457, 2017. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018. View at Publisher · View at Google Scholar · View at Scopus
  50. Institute of Medicine and National Research Council National Cancer Policy Board (US), Meeting Psychosocial Needs of Women with Breast Cancer, M. Hewitt, R. Herdman, and J. Holland, Eds., Washington, DC, USA, 2004.
  51. N. Eliyatkin, E. Yalcin, B. Zengel, S. Aktaş, and E. Vardar, “Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way,” Journal of Breast Health, vol. 11, no. 2, pp. 59–66, 2015. View at Publisher · View at Google Scholar
  52. H.-P. Sinn and H. Kreipe, “A brief overview of the WHO classification of breast tumors,” Breast Care, vol. 8, no. 2, pp. 149–154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Wu, M. Si, H.-Y. Xue, and H.-L. Wong, “Nanomedicine applications in the treatment of breast cancer: Current state of the art,” International Journal of Nanomedicine, vol. 12, pp. 5879–5892, 2017. View at Publisher · View at Google Scholar · View at Scopus
  54. S. K. Singh, S. Singh, J. W. Lillard Jr., and R. Singh, “Drug delivery approaches for breast cancer,” International Journal of Nanomedicine, vol. 12, pp. 6205–6218, 2017. View at Publisher · View at Google Scholar · View at Scopus
  55. X. Chen and J. J. Oppenheim, “Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer,” Science Signaling, vol. 10, no. 462, p. eaal2328, 2017. View at Publisher · View at Google Scholar
  56. X. Hu, B. Li, X. Li et al., “Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2,” The Journal of Immunology, vol. 192, no. 3, pp. 1320–1331, 2014. View at Publisher · View at Google Scholar
  57. X. Chen, R. Hamano, J. J. Subleski, A. A. Hurwitz, O. M. Z. Howard, and J. J. Oppenheim, “Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells,” The Journal of Immunology, vol. 185, no. 1, pp. 174–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Swanner, J. Mims, D. L. Carroll et al., “Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells,” International Journal of Nanomedicine, vol. 10, pp. 3937–3953, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Devulapally, N. M. Sekar, T. V. Sekar et al., “Polymer nanoparticles mediated codelivery of AntimiR-10b and AntimiR-21 for achieving triple negative breast cancer therapy,” ACS Nano, vol. 9, no. 3, pp. 2290–2302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Shu, H. Li, Y. Shu et al., “Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology,” ACS Nano, vol. 9, no. 10, pp. 9731–9740, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Liu, Y.-H. Zhu, C.-Q. Mao et al., “Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles,” Journal of Controlled Release, vol. 192, pp. 114–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Deng, M. Cao, J. Zhang et al., “Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer,” Biomaterials, vol. 35, no. 14, pp. 4333–4344, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. J. Deng, S. W. Morton, E. Ben-Akiva, E. C. Dreaden, K. E. Shopsowitz, and P. T. Hammond, “Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment,” ACS Nano, vol. 7, no. 11, pp. 9571–9584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Wang, J. Chen, and J. Irudayaraj, “Nuclear targeting dynamics of gold nanoclusters for enhanced therapy of HER2+ breast cancer,” ACS Nano, vol. 5, no. 12, pp. 9718–9725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. E. C. Dreaden, S. C. Mwakwari, Q. H. Sodji, A. K. Oyelere, and M. A. El-Sayed, “Tamoxifen− poly (ethylene glycol)− thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment,” Bioconjugate Chemistry, vol. 20, no. 12, pp. 2247–2253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Au, D. Zheng, F. Zhou, Z.-Y. Li, X. Li, and Y. Xia, “A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells,” ACS Nano, vol. 2, no. 8, pp. 1645–1652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. W. J. Gradishar, S. Tjulandin, N. Davidson et al., “Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7794–7803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. M. H. Bemelmans, L. J. van Tits, and W. A. Buurman, “Tumor necrosis factor: function, release and clearance,” Critical Reviews in Immunology, vol. 37, no. 2-6, pp. 249–259, 2017. View at Publisher · View at Google Scholar
  69. É. S. Vanamee and D. L. Faustman, “Structural principles of tumor necrosis factor superfamily signaling,” Science Signaling, vol. 11, no. 511, p. eaao4910, 2018. View at Publisher · View at Google Scholar
  70. J. R. Bradley, “TNF‐mediated inflammatory disease,” The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, vol. 214, no. 2, pp. 149–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. W. P. Cawthorn and J. K. Sethi, “TNF-alpha and adipocyte biology,” FEBS Letters, vol. 582, no. 1, pp. 117–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Xu, J. K. Sethi, and G. S. Hotamisligil, “Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1,” The Journal of Biological Chemistry, vol. 274, no. 37, pp. 26287–26295, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Yu, W. Shi, J. Zhang et al., “Influence of reverse signaling via membrane TNF-alpha on cytotoxicity of NK92 cells,” European Journal of Cell Biology, vol. 88, no. 3, pp. 181–191, 2009. View at Publisher · View at Google Scholar
  74. S. V. Sennikov, F. F. Vasilyev, J. A. Lopatnikova, N. S. Shkaruba, and A. N. Silkov, “Polymorphisms in the tumor necrosis factor receptor genes affect the expression levels of membrane-bound type I and type II receptors,” Mediators of Inflammation, vol. 2014, Article ID 745909, 11 pages, 2014. View at Google Scholar · View at Scopus
  75. T. Horiuchi, H. Mitoma, S.-I. Harashima, H. Tsukamoto, and T. Shimoda, “Transmembrane TNF-α: structure, function and interaction with anti-TNF agents,” Rheumatology, vol. 49, no. 7, pp. 1215–1228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. L. A. Tartaglia, D. Pennica, and D. V. Goeddel, “Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor,” The Journal of Biological Chemistry, vol. 268, no. 25, pp. 18542–18548, 1993. View at Google Scholar · View at Scopus
  77. L. A. Tartaglia and D. V. Goeddel, “Two TNF receptors,” Trends in Immunology, vol. 13, no. 5, pp. 151–153, 1992. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Hijdra, A. D. Vorselaars, J. C. Grutters, A. M. Claessen, and G. T. Rijkers, “Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes,” Journal of Inflammation (United Kingdom), vol. 9, no. 1, p. 38, 2012. View at Google Scholar · View at Scopus
  79. Z.-G. Liu, H. Hsu, D. V. Goeddel, and M. Karin, “Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death,” Cell, vol. 87, no. 3, pp. 565–576, 1996. View at Publisher · View at Google Scholar · View at Scopus
  80. L. M. Sedger and M. F. McDermott, “TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants–past, present and future,” Cytokine & Growth Factor Reviews, vol. 25, no. 4, pp. 453–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Yang, J. Wang, D. D. Brand, and S. G. Zheng, “Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications,” Frontiers in Immunology, vol. 9, 2018. View at Google Scholar · View at Scopus
  82. E.-S. Park, S. Choi, B. Shin et al., “Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction,” The Journal of Biological Chemistry, vol. 290, no. 15, pp. 9660–9673, 2015. View at Publisher · View at Google Scholar
  83. E.-W. Lee, J. Seo, M. Jeong, S. Lee, and J. Song, “The roles of FADD in extrinsic apoptosis and necroptosis,” BMB Reports, vol. 45, no. 9, pp. 496–508, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Michel, I. Wilhelmi, A.-S. Schultz, M. Preussner, and F. Heyd, “Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor κB pathway and chemokine expression in human T cells,” The Journal of Biological Chemistry, vol. 289, no. 19, pp. 13651–13660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. A. J. McPherson, L. M. Snell, T. W. Mak, and T. H. Watts, “Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells,” The Journal of Biological Chemistry, vol. 287, no. 27, pp. 23010–23019, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. S. C. Sun, “The noncanonical NF-kappaB pathway,” Immunological Reviews, vol. 246, no. 1, pp. 125–140, 2012. View at Google Scholar
  87. P. Xie, Z. J. Kraus, L. L. Stunz, Y. Liu, and G. A. Bishop, “TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling,” The Journal of Immunology, vol. 186, no. 1, pp. 143–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Mercer and D. Unutmaz, “The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer,” Advances in Experimental Medicine and Biology, vol. 665, pp. 47–59, 2009. View at Google Scholar
  89. X. Chen, J. J. Subleski, H. Kopf, O. M. Zack Howard, D. N. Männel, and J. J. Oppenheim, “Cutting Edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells,” The Journal of Immunology, vol. 180, no. 10, pp. 6467–6471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. Grinberg-Bleyer, D. Saadoun, A. Baeyens et al., “Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting tregs,” The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4558–4568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. X. Chen, M. Baumel, D. N. Mannel, O. M. Howard, and J. J. Oppenheim, “Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T Regulatory Cells,” The Journal of Immunology, vol. 179, no. 1, pp. 154–161, 2007. View at Publisher · View at Google Scholar
  92. A. Baeyens, D. Saadoun, F. Billiard et al., “Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context,” The Journal of Immunology, vol. 194, no. 3, pp. 999–1010, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Szlosarek, K. A. Charles, and F. R. Balkwill, “Tumour necrosis factor-α as a tumour promoter,” European Journal of Cancer, vol. 42, no. 6, pp. 745–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Kalthoff, C. Roeder, M. Brockhaus, H.-G. Thiele, and W. Schmiegel, “Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA,” The Journal of Biological Chemistry, vol. 268, no. 4, pp. 2762–2766, 1993. View at Google Scholar · View at Scopus
  95. F. Yang, N. Zhao, and N. Wu, “TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage,” Molecular Medicine Reports, vol. 16, no. 3, pp. 2962–2968, 2017. View at Publisher · View at Google Scholar · View at Scopus
  96. Z. Zhong, K. D. Carroll, D. Policarpio et al., “Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells,” Clinical Cancer Research, vol. 16, no. 4, pp. 1191–1205, 2010. View at Publisher · View at Google Scholar
  97. M. A. Rivas, R. P. Carnevale, C. J. Proietti et al., “TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways,” Experimental Cell Research, vol. 314, no. 3, pp. 509–529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. S. P. Sasi, S. Bae, J. Song, A. Perepletchikov, and D. Schneider, “Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants,” PLoS ONE, vol. 9, no. 3, Article ID e92373, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Richter, S. Messerschmidt, G. Holeiter et al., “The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand,” Molecular and Cellular Biology, vol. 32, no. 13, pp. 2515–2529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. J. L. Cohen and K. J. Wood, “TNFR2: the new Treg switch?” OncoImmunology, vol. 7, no. 1, Article ID e1373236, 2018. View at Publisher · View at Google Scholar
  101. I. Martínez-Reza, L. Díaz, and R. García-Becerra, “Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer,” Journal of Biomedical Science, vol. 24, no. 1, p. 90, 2017. View at Google Scholar · View at Scopus
  102. F. Yang, Z. Zhao, and N. Zhao, “Clinical implications of tumor necrosis factor receptor 2 in breast cancer,” Oncology Letters, vol. 14, no. 2, pp. 2393–2398, 2017. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Nie, J. He, H. Shirota et al., “Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer,” Science Signaling, vol. 11, no. 511, p. eaan0790, 2018. View at Publisher · View at Google Scholar
  104. R. S. Al-Lamki, T. J. Sadler, J. Wang et al., “Tumor necrosis factor receptor expression and signaling in renal cell carcinoma,” The American Journal of Pathology, vol. 177, no. 2, pp. 943–954, 2010. View at Publisher · View at Google Scholar
  105. J. Wang and R. S. Al-Lamki, “Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma,” BioMed Research International, vol. 2013, Article ID 821310, 11 pages, 2013. View at Google Scholar · View at Scopus
  106. R. G. Van Der Most, A. J. Currie, S. Mahendran et al., “Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy,” Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1219–1228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. L.-L. Ye, X.-S. Wei, M. Zhang, Y.-R. Niu, and Q. Zhou, “The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells,” Frontiers in Immunology, vol. 9, p. 583, 2018. View at Google Scholar · View at Scopus
  108. H. Torrey, J. Butterworth, T. Mera et al., “Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs,” Science Signaling, vol. 10, no. 462, Article ID eaaf8608, 2017. View at Publisher · View at Google Scholar · View at Scopus
  109. K. Hyrich, “Tumor necrosis factor-alpha inhibitors: risk of malignancy,” UpToDate, 2018. View at Google Scholar
  110. L. M. Sedger and M. F. McDermott, “TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future,” Cytokine & Growth Factor Reviews, vol. 25, no. 4, pp. 453–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. E. Tobinick, “Perispinal etanercept: a new therapeutic paradigm in neurology,” Expert Review of Neurotherapeutics, vol. 10, no. 6, pp. 985–1002, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Marotte and R. Cimaz, “Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?” Expert Opinion on Biological Therapy, vol. 14, no. 5, pp. 569–572, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. H. Zou, R. Li, H. Hu, Y. Hu, and X. Chen, “Modulation of regulatory T cell activity by TNF receptor type II-targeting pharmacological agents,” Frontiers in Immunology, vol. 9, p. 594, 2018. View at Publisher · View at Google Scholar
  115. D. Siegmund, J. Kums, M. Ehrenschwender, and H. Wajant, “Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis,” Cell Death & Disease, vol. 7, no. 9, Article ID e2375, 2016. View at Google Scholar · View at Scopus
  116. Y. Sheng, F. Li, and Z. Qin, “TNF receptor 2 makes tumor necrosis factor a friend of tumors,” Frontiers in Immunology, vol. 9, 2018. View at Google Scholar · View at Scopus
  117. R. Bazak, M. Houri, S. El Achy, S. Kamel, and T. Refaat, “Cancer active targeting by nanoparticles: a comprehensive review of literature,” Journal of Cancer Research and Clinical Oncology, vol. 141, no. 5, pp. 769–784, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. R. Mohamud, S. D. Xiang, C. Selomulya et al., “The effects of engineered nanoparticles on pulmonary immune homeostasis,” Drug Metabolism Reviews, vol. 46, no. 2, pp. 176–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Mohamud, J. S. LeMasurier, J. C. Boer et al., “Synthetic nanoparticles that promote tumor necrosis factor receptor 2 expressing regulatory T cells in the lung and resistance to allergic airways inflammation,” Frontiers in Immunology, vol. 8, p. 1812, 2017. View at Publisher · View at Google Scholar